Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2013

View Archived Issues

Discovery of ATPase inhibitors that disrupt protein homeostasis to induce cancer cell death

Lpath receives NIH grant for Lpathomab

Nektar Therapeutics develop a novel (PEG)-taxane conjugate with improved in vivo efficacy

AM-Pharma begins phase I trial with new recombinant AP product

Agios Pharmaceuticals enrolls first patient in phase I AG-221 study

Preliminary phase I results demonstrate AVI-7288 to be well tolerated

AbbVie and Galapagos form global alliance to develop cystic fibrosis therapies

JDRF partners with AGTC and Genzyme for diabetic retinopathy-caused blindness

BioLineRx files to initiate phase I/II celiac disease study in Finland

AstraZeneca licenses three drug discovery programs from X-Chem

Quartette launched in U.S.

Bayer receives Canadian approval for riociguat in thromboembolic pulmonary hypertension

Weekly and monthly regimens of langlenatide well tolerated in phase IIa study

U.S. government selects Evolva antibiotic for possible preclinical funding

Neurovance begins phase II study of EB-1020 SR in adults with ADHD

Phase II data presented for subcutaneous BNP in patients with preclinical diastolic dysfunction

NuPathe doses adolescent patients in phase I Zecuity trial

Topline results from phase II retaspimycin hydrochloride study reported

Boehringer Ingelheim gains E.U. approval for afatinib

First approval in Europe for Gilead Sciences' cobicistat

Takeda files for approval of Hib vaccine in Japan

Merck KGaA develops GCN2/SYK inhibitors

Deciphera and Lilly jointly disclose novel B-raf inhibitors

Amgen patents Na(v)1.7 sodium channel blockers

GE Healthcare and UCL School of Pharmacy report discovery of potential diagnostic agents

SBI Pharmaceuticals launches malignant glioma diagnostic in Japan

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...